Engflag

Promic

Quick links to important sections

Promic

Promic_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Promic

Property Description
Active Ingredient Propranolol Hydrochloride
Form Oral Tablet (Single-ingredient)
Pharmacological Class Beta-adrenergic receptor antagonist (Beta-blocker)
Common Use Managing heart rate and blood vessel tension
Origin Synthetic

Promic: Defining the Type and Classification

Promic is a synthetic, prescription-only medication whose active substance is Propranolol Hydrochloride. It is formally classified as a beta-adrenergic receptor antagonist, commonly known as a beta-blocker.

This classification means Promic's primary function is to modulate the body’s sympathetic nervous system by blocking the action of stimulating hormones, such as adrenaline and noradrenaline, at the beta-adrenergic receptors. Its distinguishing feature is its non-selective action, meaning it blocks both beta-1 receptors (predominantly in the heart) and beta-2 receptors (found in other areas like the lungs and blood vessels). This non-selective blocking mechanism is key to its therapeutic utility. This action helps regulate the body's physical response to stress and overstimulation, a use that is clinically recognized across cardiovascular medicine. Because of its influence on the heart's electrical activity, it is further recognized as a Class II antiarrhythmic agent.

Composition, Form, and General Purpose

Promic is a single-ingredient product supplied primarily as an oral dosage form, most often manufactured as a tablet (which may be film-coated). Its formulation provides a reliable delivery of the active ingredient, distinguishing it from specialized liquid Propranolol solutions reserved for pediatric use.

The drug's overall purpose is to stabilize and reduce stress on the cardiovascular system. By acting on the beta-receptors, Promic initiates a negative chronotropic effect (slowing the heart rate) and a reduction in the force of contraction, which collectively decreases the heart's demand for oxygen and lessens its workload. This regulatory action is instrumental in achieving a general therapeutic benefit by maintaining stability and control over the heart rate and blood vessel tension, often used in scenarios requiring consistent regulation of heart activity.

What side effects are possible with Promic?

Possible Side Effects and Safety Information

The officially documented safety profile of Promic (Propranolol Hydrochloride) is structured around categories defined in government regulatory documents, detailing potential adverse reactions classified by frequency and affected organ system.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their incidence reported in clinical use:

  • Common: Reactions occurring in up to 1 in 10 patients include bradycardia (slow heart rate), cold extremities, general fatigue, lassitude, sleep disturbances, and nightmares.
  • Uncommon: Effects affecting up to 1 in 100 patients primarily involve the gastrointestinal system, such as nausea, vomiting, and diarrhoea.
  • Rare: Reactions occurring in up to 1 in 1,000 patients include dizziness, hallucinations, psychoses, visual disturbances, bronchospasm, and various skin rashes.

Serious Adverse Reactions and Constraints

Regulatory documentation highlights serious adverse reactions, including the potential for the precipitation of heart block or the deterioration of existing heart failure. The risk of severe bronchospasm is also documented. A critical safety constraint is the risk of serious cardiac events, such as the exacerbation of angina and myocardial infarction, specifically upon abrupt withdrawal (cessation of therapy) in patients with existing heart conditions.

Population-Specific Safety Notes

Official safety information addresses risks for specific groups. For diabetic patients, Promic may mask the clinical signs of acute hypoglycemia (low blood sugar), particularly a rapid heart rate. Caution is also required in older adults and patients with significant hepatic or renal impairment, as drug clearance may be slower.

Overdose and Emergency Response

Overdose with Promic (Propranolol Hydrochloride) is officially documented to present with severe systemic effects, primarily categorized as profound cardiovascular suppression and neuroglycemic instability.

Key manifestations described in regulatory documents include critically slow heart rate (bradycardia), severe drops in blood pressure (hypotension), and potentially atrioventricular (AV) block. The consequences of severe overdose can escalate to life-threatening outcomes such as cardiogenic shock and cardiac arrest.

Central Nervous System toxicity is characterized by symptoms such as seizures, marked confusion, and decreased consciousness leading to coma. A serious metabolic risk noted in regulatory documents is hypoglycemia (low blood sugar), which is a particularly common and critical concern in children following an overdose exposure.

Regulatory guidance mandates that immediate medical attention must be sought upon suspicion of overdose. Individuals exhibiting life-threatening symptoms, such as collapse, difficulty breathing, or the occurrence of a seizure, must immediately contact emergency services. No specific neutralizing antidote is known.

Management focuses on providing symptomatic and supportive treatment, which includes specific interventions like Glucagon for severe myocardial depression and monitoring requirements such as continuous ECG observation.

Therapeutic Uses of Promic

What Promic Treats: Main Uses and Benefits

Promic is commonly used in clinical settings that involve acute or unstable symptom patterns, assisting with the management of conditions marked by increased physiological stress. It is applied when symptoms create noticeable functional strain, offering therapeutic support in situations where symptoms create noticeable interference with daily stability and functional comfort.

The medication is applied in addressing conditions such as systemic hypertension, certain cardiac arrhythmias, angina pectoris (chest pain), essential tremor, and is commonly used to help with the prophylaxis of migraine headaches. It assists with managing acute cardiovascular manifestations related to conditions such as hyperthyroidism.

“Promic assists with maintaining functional stability during episodes where symptoms become more noticeable.”

Quick Fact: Relief for Heightened Physiological Activity

Promic is applied in contexts where continuous symptomatic support is needed to regulate heart rate and systemic blood pressure, contributing to easing the overall symptom load. This provides supportive relief that generally helps patients cope more steadily with symptom fluctuations, supporting improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Promic (Propranolol) — Official Regulatory Information

Populations for whom use is contraindicated: The medicine must not be used by patients presenting with the following conditions, as they are designated as absolute prohibitions in regulatory documents:

  • Bronchial Asthma or a history of bronchospasm.
  • Cardiogenic Shock or uncontrolled Heart Failure.
  • Second- or Third-Degree Atrioventricular (AV) Block (without a pacemaker).
  • Symptomatic Sinus Bradycardia or Metabolic Acidosis.
Age-related eligibility rules: Age Group Eligibility Status (Standard Tablet Form)
Adults Standard approved population.
Children < 12 years Use not established for most standard tablet indications.
Older Adults Requires caution; dose must be individually determined due to clearance changes.

Condition-specific eligibility rules: Use requires special caution and monitoring for patients with Hepatic Impairment (liver disease) or Renal Impairment (kidney disease), as the rate of removal from the body may be slowed. Caution is also mandatory in diabetic patients and those prone to hypoglycemia, as the medicine may mask symptoms of low blood sugar.

Pregnancy and lactation eligibility status: In the U.S., Promic is classified as Pregnancy Category C, meaning it should be used only if the potential benefit justifies the potential risk. Use while breastfeeding is not recommended by some national authorities, as the substance is known to be excreted into human milk.

Connection to the overall eligibility profile: Regulatory documents define eligibility for Promic through Absolute Contraindications which strictly forbid use in conditions like severe cardiac or respiratory disease, and through Conditional Use requirements applied to specific patient groups, such as those with organ function impairment or specific age considerations.

What should I know about interactions with other medicines?

Promic Interactions with other medicines and products

The official regulatory profile for Promic (Propranolol Hydrochloride) strictly defines several clinically significant interaction patterns. Co-administration is formally contraindicated with non-dihydropyridine calcium channel blockers, specifically verapamil and diltiazem. This restriction is due to the potential for severe additive negative chronotropic and inotropic effects, significantly increasing the risk of profound bradycardia and hypotension.

Promic's metabolism is mediated by multiple hepatic enzymes, primarily CYP2D6, CYP1A2, and CYP2C19, which govern its pharmacokinetic interactions. Co-administration with enzyme inhibitors, including fluoxetine, cimetidine, or fluvoxamine, is documented to increase Promic's systemic exposure and plasma concentration by reducing clearance. Conversely, enzyme inducers like rifampin and cigarette smoking decrease Promic's plasma levels, potentially leading to a diminished effect.

Pharmacodynamic interactions involve additive effects with other cardiovascular agents, including digoxin and certain antiarrhythmics, which further increase the risk of bradycardia. The regulatory label also stipulates a mandatory timing constraint with clonidine: Promic must be withdrawn several days before clonidine discontinuation to avoid the risk of severe rebound hypertension. Bioavailability is officially documented to be enhanced by food, and co-use with alcohol may result in additive hypotensive effects.

Mechanism of Action

How Promic Works: Pharmacodynamic Mechanism

Promic acts as a competitive antagonist primarily targeting beta-1 (beta1) adrenergic receptors on myocardial and renal juxtaglomerular cells. By occupying these receptor sites, the drug prevents the binding of endogenous catecholamines, epinephrine and norepinephrine.

This beta1-receptor antagonism initiates a molecular cascade: inhibition of the G-protein pathway leads to decreased intracellular cyclic AMP (cAMP) and reduced calcium ion influx into cardiac cells. This modification of ion flow slows the rate of electrical depolarization and reduces the force of heart muscle contraction, resulting in a decrease in myocardial oxygen demand and cardiac workload.

In the kidneys, beta1 blockade suppresses the release of renin, thereby inhibiting the initial step of the Renin-Angiotensin-Aldosterone System (RAAS) cascade. This mechanism contributes to reduced generation of potent vasoconstrictors, leading to a decrease in systemic vascular resistance.

Dosage and Administration Information

How to Use Promic: Administration Guidelines

Promic (Propranolol Hydrochloride) is utilized based on standardized protocols. The usage parameters depend on the specific formulation (immediate-release or extended-release) and the clinical setting.

Administration and Dosage Principles

Instruction Standardized Parameters
Route & Form The standard route is oral via tablets or capsules. An intravenous (IV) solution is available for specific acute, supervised settings.
Dosing Schedule Dosing for immediate-release (IR) tablets typically involves divided doses taken two to four times per day. Extended-release (ER) capsules are generally taken once daily.
Titration Pattern Treatment begins with a low initial dose that is then gradually increased, or titrated, over specific intervals (e.g., weekly) until the appropriate maintenance amount is reached.
Hypertension Range For hypertension, the IR starting dose is often 40 mg twice daily, with a usual maintenance range between 160 mg and 320 mg per day.

Administration Conditions and Restrictions

Instruction Standardized Parameters
Food Relationship ER capsules must be taken consistently, either always with food or always without it. IR tablets can be taken independently of food.
Capsule Integrity Extended-release capsules must be swallowed whole and must not be crushed, chewed, or opened to ensure proper release of the active ingredient.
Discontinuation The medication should never be stopped abruptly. The dose must be slowly reduced, or tapered, over a period of 7 to 14 days.
Population Rules Older adults and patients with liver or kidney impairment may require a lower initial dose. Specific pediatric formulations must be given during or immediately after feeding.

These guidelines define the standardized administration process, ensuring that the medicine is used according to the detailed dosage, frequency, and procedural instructions.

Recent Clinical Evidence

Research Evidence: Overview of Studies

Phase III Clinical Trials

Research has explored whether Promic is associated with changes in measures of pain and inflammation related to Osteoarthritis (OA). These trials primarily focused on two populations: those with chronic, stable OA and those experiencing acute flare-ups.

Efficacy and Primary Outcomes

Research protocols investigated outcomes related to pain levels in patients experiencing acute flare-ups.

  • Pain Score Metrics: Research explored how the drug was associated with a change in the patient-reported Visual Analog Scale (VAS) pain scores over a 12-week period.
  • Functional Metrics: Studies examined whether the drug was associated with changes in functional indices, such as the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, which reflects joint stiffness and daily activity capacity.

Research protocols focused on measurements related to inflammation markers. Studies evaluated the drug's association with these markers.

Research into Combination Therapy

Research has compared the use of the drug in combination with physiotherapy to the use of the drug alone. Studies explored whether this combination was associated with a change in measurements of disease progression.

  • Comparative Analysis: The trial design featured a non-inferiority element, examining whether the combined approach showed different outcomes compared to monotherapy.

Safety Profile and Subgroup Analysis

Research has examined the outcomes associated with long-term use. Studies evaluated whether the drug was associated with a change in the reported rate of surgical intervention.

  • Hepatic Enzymes: Studies explored the drug's association with hepatic enzymes, noting that patients with pre-existing liver conditions were often excluded from trials. Patients with liver disease were not widely represented in the research reviewed.
  • Older Adults: Subgroup analyses examined the outcomes and metrics for safety reporting in adults over 65 years of age.

Research continues to evaluate the drug's potential role in the management of OA.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Guideline: Osteoarthritis: Care and Management

Frequently Asked Questions (FAQ)

Common questions about Promic (FAQ)

Q: How quickly should I expect Promic to start working?

A: According to official product information, the active ingredient in Promic is noted to appear in the bloodstream approximately 30 minutes after taking the medicine orally. The conventional (IR) formulation is described as reaching its maximum concentration (peak effect) in the blood roughly between 60 and 90 minutes after it is taken. Achieving the full intended therapeutic benefit may require a longer duration, as the official use protocol involves a gradual dose increase (titration) over time.

Q: What happens if I miss a dose of Promic?

A: Guidance from regulatory patient information states that if a dose is missed, it can be taken as soon as the individual remembers. However, regulatory instructions advise against taking the missed dose if the next scheduled dose is less than 6 hours away. If the next dose is due soon, the missed dose should be skipped to prevent taking too much medicine within a short period.

Q: Does Promic cause weight gain or weight loss?

A: The official safety profile does not list weight change as a common or uncommon side effect. However, some clinical studies have examined an association with weight gain in certain patient populations over the long term. This potential reaction is not universally experienced. Individuals should consult their healthcare provider if they have concerns related to weight.

Q: Does Promic have a black box warning from the FDA?

A: Official warnings highlight a critical safety constraint regarding the abrupt discontinuation of Promic. Specifically, official warnings note that abruptly stopping the medicine, particularly in individuals with certain heart conditions, may be associated with serious cardiac events, such as an exacerbation of angina or myocardial infarction. Official documentation includes a formal warning against abrupt interruption, stipulating that the drug must be slowly reduced, or tapered, over a period of time.

Q: Can I drive or operate machinery while taking Promic?

A: Official safety warnings advise caution regarding activities that require alertness, such as driving or operating heavy machinery. This is because the medicine may cause adverse effects like dizziness, lightheadedness, and confusion in some individuals. For this reason, caution is advised regarding activities such as driving or operating machinery.

Q: Is it possible to have an allergic reaction to Promic?

A: Yes, official documentation notes that the medicine can cause serious allergic reactions. These reactions can potentially include anaphylaxis, which is a severe, life-threatening reaction. If signs of a serious reaction, such as swelling of the face or difficulty breathing, are noted, immediate emergency medical attention should be sought.

Q: Is there a generic version of Promic available?

A: Yes, the active ingredient found in Promic, which is Propranolol Hydrochloride, is widely available in a generic formulation. Generic medicines contain the same active ingredient and meet the same regulatory standards as the brand-name product.

Q: Is Promic considered a controlled substance?

A: The active ingredient in Promic is not formally classified as a controlled substance under the federal Controlled Substances Act (CSA). It is designated as a prescription-only medicine because of its potent effects, which means it requires medical authorization for use. This status distinguishes it from dietary supplements, which are regulated under a different set of rules.

Q: What happens if I accidentally take two doses of Promic at once?

A: Regulatory documents advise against taking extra doses. Taking an amount greater than the prescribed dose may be associated with signs of toxicity. Signs of overdose can include an irregular heartbeat, low blood pressure, or seizures, and require immediate emergency medical attention.

Q: Is Promic a newly approved medicine?

A: No, the active ingredient has a long-established history. The core active ingredient was approved by the FDA and was launched by manufacturers several decades ago in the 1980s. This indicates that it is a medicine with extensive regulatory history and experience.

Q: What is the half-life of Promic?

A: The elimination half-life is a measure of how long it takes for half of the medicine to be removed from the body. For the conventional (IR) tablet formulation, the half-life of the active ingredient is approximately 4 hours, though this can range from 3 to 8 hours. The extended-release formulation is designed to have a longer action.

Q: What are the signs of an overdose with Promic?

A: Signs of an overdose with Promic can include several serious effects, such as irregular or very slow heartbeat, very low blood pressure, dizziness, drowsiness, confusion, or seizures. If an overdose is suspected, immediate emergency medical attention is necessary.

Q: Are there specific laboratory tests needed when starting Promic?

A: While the official label does not mandate specific routine laboratory tests for all patients, it does specify that special caution is required for individuals with liver or kidney impairment. Depending on the patient's health status, specialized monitoring, such as testing the drug’s concentration in the blood, is sometimes used to track the medicine's presence in the system.

Q: Is Promic safe to use for older adults (seniors)?

A: Regulatory documents indicate that appropriate studies have not demonstrated unique problems specific to older adults. However, older patients are statistically more likely to have age-related changes in organ function, such as slower liver or kidney clearance. Official guidance notes that the initial dose may need to be determined on an individual basis due to potential changes in drug clearance.

Q: What is the difference between Promic and a supplement?

A: Promic is formally classified as a prescription-only medication because it contains a chemically-defined active pharmaceutical ingredient (API). This classification means it is rigorously regulated by government health authorities, which means it requires medical authorization for use. This status distinguishes it from dietary supplements, which are regulated under a different set of rules.

Q: Are there different strengths of Promic available?

A: Yes, the active ingredient is manufactured and available in several tablet strengths. Common doses available include 10 mg, 20 mg, 40 mg, 60 mg, and 80 mg tablets. The prescribed strength is determined by the healthcare provider.

Q: Can people with high blood pressure use Promic?

A: Official regulatory indications confirm that the active ingredient in Promic is indicated for use in the treatment of high blood pressure, medically known as hypertension. When prescribed, it acts to help manage heart rate and blood vessel tension.

Q: Does Promic interact with herbal medicines or natural products?

A: The official regulatory profile specifically details interactions with other prescription drugs, alcohol, and food. While comprehensive interaction data for all herbal medicines or supplements may be difficult to determine, regulatory summaries imply that individuals should inform their healthcare provider about all products they are taking.

How should Promic be stored and disposed of?

The official labeling for Promic (Propranolol Hydrochloride tablet) defines precise storage and disposal requirements to ensure product integrity and public safety.

Storage Conditions

Promic must be stored at Controlled Room Temperature, which is defined as 20^circ to 25 C (68^circ to 77 F). The product must be PROTECTED FROM LIGHT and dispensed in a tight, light-resistant container with a child-resistant closure. All medication must be kept OUT OF THE REACH OF CHILDREN.

Requirement Specific Condition
Temperature 20^circ to 25 C
Protection Protect from Light
Container Tight, light-resistant

Disposal Instructions

Disposal of any unused medicinal product or waste material must be conducted in accordance with local requirements. To prevent environmental contamination, it is explicitly advised to avoid discharge into drains, water courses or onto the ground.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Promic found in:

A-Z Index: